感染新型冠状病毒的2型糖尿病患者的临床特征和结果——一项回顾性研究

• Published in: 工程（英文） Vol. 6; no. 10; pp. 1170 - 中插138
• Main Authors: 陈滢宇, 陈剑坤, 宫晓, 荣向路, 叶得伟, 金英花, 张忠德, 李际强, 郭姣
• Format: Journal Article
• Language: Chinese
• Published: Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China & Key Unit of Modulating Liver to Treat Hyperlipemia SATCM & Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China%The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou 510120, China 2020; The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, China; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou 510120, China%School of Public Health, Guangdong Pharmaceutical University, Guangzhou 510006, China%Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China & Key Unit of Modulating Liver to Treat Hyperlipemia SATCM & Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China
• Subjects: COVID-19; 临床特征; Comorbidities; 新冠病毒肺炎; Coronavirus disease; Clinical characteristics; 冠状病毒; Diabetes; 糖尿病; 合并症
• ISSN: 2095-8099

据报道,糖尿病及其相关的代谢性疾病是新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)患者的主要合并症.这项临床研究旨在调查有或没有合并糖尿病的COVID-19患者的临床特征、影像学和实验室检查、并发症、治疗方法以及临床结局.这项回顾性研究纳入2020年1月12日至3月25日208例经实验室确认的COVID-19的住院患者(≥45岁).分析病历信息包括临床特征、影像学和实验室检查、并发症、治疗和临床结果.其中,96名(46.2％)患者患有2型糖尿病.在COVID-19合并2型糖尿病患者中,高血压(58.3％vs.31.2％)、冠心病(17.1％vs.8.0％)和慢性肾脏病(6.2％vs.0％)的共存率明显高于没有2型糖尿病的COVID-19患者.COVID-19合并2型糖尿病患者的CT胸部扫描异常频率和程度显著增加,包括毛玻璃样混浊(85.6％vs.64.9％,P<0.001)和双侧斑片状阴影(76.7％vs.37.8％,P<0.001).此外,患有糖尿病的COVID-19患者的血糖水平[7.23 mmol·L?1(IQR:5.80～9.29)vs.5.46 mmol·L?1(IQR:5.00～6.46)]、血液中低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)[2.21 mmol·L?1(IQR:1.67～2.76)vs.1.75 mmol·L?1(IQR:1.27～2.01)]和收缩压[130 mmHg(IQR:120～142)vs.122 mmHg(IQR:110～137),P<0.001]显著高于没有糖尿病的患者(P<0.001).2型糖尿病和其他代谢性疾病共存于COVID-19患者中,这可能会增加发病率并加重COVID-19的病情.血糖和脂质代谢的最佳管理是确保更好的临床结果的关键.对于患有糖尿病及其他基础和慢性代谢性疾病的COVID-19患者,应提高临床警惕性.